| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802422201014 | 242220101 | ZEFFIX F.C.TAB 100MG/TAB BTX28(BLISTERS) | 19.17 | 20.11 | 27.71 |
| 05/2018 | 2802422202011 | 242220201 | ZEFFIX ORAL.SOL 5MG/ML FLX240ML | 9.83 | 10.31 | 14.20 |
For the treatment of HIV infection and chronic hepatitis B (HBV).
Lamivudine is a synthetic nucleoside analogue and is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP). This nucleoside analogue is incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase, resulting in DNA chain termination.
Lamivudine was rapidly absorbed after oral administration in HIV-infected patients. Absolute bioavailability in adults is 86% ± 16% for the tablet and 87% ± 13% for the oral solution.
5 to 7 hours
The primary routes of elimination of abacavir are metabolism by alcohol dehydrogenase to form the 5′-carboxylic acid and glucuronyl transferase to form the 5′-glucuronide. Lamivudine is excreted in human breast milk and into the milk of lactating rats.
* Renal cl=280.4 +/- 75.2 mL/min [HIV-infected patients given a single IV doses ranging from 0.25 to 8 mg/kg]